
## Matthew S Parsons

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5710108/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 Delta infection. Science Immunology, 2022, 7, eabo0226.	11.9	22
2	Enhancement of Antibody-Dependent Cellular Cytotoxicity and Phagocytosis in Anti-HIV-1 Human-Bovine Chimeric Broadly Neutralizing Antibodies. Journal of Virology, 2021, 95, e0021921.	3.4	7
3	Application of an evidence-based, out-patient treatment strategy for COVID-19: Multidisciplinary medical practice principles to prevent severe disease. Journal of the Neurological Sciences, 2021, 426, 117463.	0.6	0
4	Potential Utility of Natural Killer Cells for Eliminating Cells Harboring Reactivated Latent HIV-1 Following the Removal of CD8+ T Cell-Mediated Pro-Latency Effect(s). Viruses, 2021, 13, 1451.	3.3	0
5	Protective efficacy of the anti-HIV broadly neutralizing antibody PGT121 in the context of semen exposure. EBioMedicine, 2021, 70, 103518.	6.1	3
6	Anti-Drug Antibodies in Pigtailed Macaques Receiving HIV Broadly Neutralising Antibody PGT121. Frontiers in Immunology, 2021, 12, 749891.	4.8	4
7	Mitigating alemtuzumab-associated autoimmunity in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	15
8	High CD26 and Low CD94 Expression Identifies an IL-23 Responsive Vδ2+ T Cell Subset with a MAIT Cell-like Transcriptional Profile. Cell Reports, 2020, 31, 107773.	6.4	32
9	Short Communication: Effect of Seminal Plasma on Functions of Monocytes and Granulocytes. AIDS Research and Human Retroviruses, 2019, 35, 553-556.	1.1	3
10	Impact of HIVâ€1 viremia or sexually transmitted infection on semenâ€derived antiâ€HIVâ€1 antibodies and the immunosuppressive capacity of seminal plasma. European Journal of Immunology, 2019, 49, 2255-2258.	2.9	1
11	Modulation of the CCR5 Receptor/Ligand Axis by Seminal Plasma and the Utility of <i>In Vitro</i> versus <i>In Vivo</i> Models. Journal of Virology, 2019, 93, .	3.4	3
12	CD4- and Time-Dependent Susceptibility of HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity. Journal of Virology, 2019, 93, .	3.4	11
13	Influenza Virus Infection Enhances Antibody-Mediated NK Cell Functions via Type I Interferon-Dependent Pathways. Journal of Virology, 2019, 93, .	3.4	33
14	Two Families of Env Antibodies Efficiently Engage Fc-Gamma Receptors and Eliminate HIV-1-Infected Cells. Journal of Virology, 2019, 93, .	3.4	44
15	Contribution of NK Cell Education to both Direct and Anti-HIV-1 Antibody-Dependent NK Cell Functions. Journal of Virology, 2018, 92, .	3.4	17
16	HIV Reactivation after Partial Protection by Neutralizing Antibodies. Trends in Immunology, 2018, 39, 359-366.	6.8	6
17	Neutralizing Antibody-Based Prevention of Cell-Associated HIV-1 Infection. Viruses, 2018, 10, 333.	3.3	7
18	Uninfected Bystander Cells Impact the Measurement of HIV-Specific Antibody-Dependent Cellular Cytotoxicity Responses. MBio, 2018, 9, .	4.1	82

MATTHEW S PARSONS

#	Article	IF	CITATIONS
19	Importance of Fc-mediated functions of anti-HIV-1 broadly neutralizing antibodies. Retrovirology, 2018, 15, 58.	2.0	32
20	Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques. Journal of Clinical Investigation, 2018, 129, 182-191.	8.2	69
21	Beyond Viral Neutralization. AIDS Research and Human Retroviruses, 2017, 33, 760-764.	1.1	36
22	Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses. Journal of Virology, 2017, 91, .	3.4	52
23	Impaired Downregulation of NKG2D Ligands by Nef Proteins from Elite Controllers Sensitizes HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity. Journal of Virology, 2017, 91, .	3.4	30
24	Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption. Journal of Virology, 2017, 91, .	3.4	14
25	Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection. Science Translational Medicine, 2017, 9, .	12.4	45
26	Fc functional antibodies in humans with severe H7N9 and seasonal influenza. JCI Insight, 2017, 2, .	5.0	39
27	Modulation of innate and adaptive cellular immunity relevant to HIV-1 vaccine design by seminal plasma. Aids, 2017, 31, 333-342.	2.2	13
28	Brief Report. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 17-23.	2.1	17
29	The Significance of a Common Idiotype (1F7) on Antibodies against Human Immune Deficiency Virus Type 1 and Hepatitis C Virus. Frontiers in Oncology, 2016, 6, 11.	2.8	2
30	NKG2D Acts as a Co-Receptor for Natural Killer Cell-Mediated Anti-HIV-1 Antibody-Dependent Cellular Cytotoxicity. AIDS Research and Human Retroviruses, 2016, 32, 1089-1096.	1.1	31
31	DC-SIGN and L-SIGN Are Attachment Factors That Promote Infection of Target Cells by Human Metapneumovirus in the Presence or Absence of Cellular Glycosaminoglycans. Journal of Virology, 2016, 90, 7848-7863.	3.4	9
32	What Lies Beneath: Antibody Dependent Natural Killer Cell Activation by Antibodies to Internal Influenza Virus Proteins. EBioMedicine, 2016, 8, 277-290.	6.1	67
33	Antibody-Dependent Cellular Cytotoxicity against Reactivated HIV-1-Infected Cells. Journal of Virology, 2016, 90, 2021-2030.	3.4	53
34	λ Light Chain Bias Associated With Enhanced Binding and Function of Anti-HIV Env Glycoprotein Antibodies. Journal of Infectious Diseases, 2016, 213, 156-164.	4.0	18
35	Paradox of Protection: Preferential Recognition of CD4-induced Epitopes by Anti-HIV-1 ADCC Antibodies. EBioMedicine, 2015, 2, 1298-1299.	6.1	0
36	Slaying the Trojan Horse: Natural Killer Cells Exhibit Robust Anti-HIV-1 Antibody-Dependent Activation and Cytolysis against Allogeneic T Cells. Journal of Virology, 2015, 89, 97-109.	3.4	42

MATTHEW S PARSONS

#	Article	IF	CITATIONS
37	Antibody-Dependent Effector Functions Against HIV Decline in Subjects Receiving Antiretroviral Therapy. Journal of Infectious Diseases, 2015, 211, 529-538.	4.0	28
38	Anti-HIV Antibody–Dependent Activation of NK Cells Impairs NKp46 Expression. Journal of Immunology, 2014, 192, 308-315.	0.8	39
39	Role of education and differentiation in determining the potential of natural killer cells to respond to antibody-dependent stimulation. Aids, 2014, 28, 2781-2786.	2.2	20
40	The maturation of antibody technology for the HIV epidemic. Immunology and Cell Biology, 2014, 92, 570-577.	2.3	6
41	Selection of human anti-HIV broadly neutralizing antibodies occurs within the context of frozen 1F7-idiotypic repertoire. Aids, 2011, 25, 1249-1264.	2.2	9
42	Distinct Phenotype of Unrestricted Cytotoxic T lymphocytes from Human Immunodeficiency Virus-infected Individuals. Journal of Clinical Immunology, 2010, 30, 272-279.	3.8	1
43	Killer cell immunoglobulin-like receptor 3DL1 licenses CD16-mediated effector functions of natural killer cells. Journal of Leukocyte Biology, 2010, 88, 905-912.	3.3	46
44	Natural Killer Cell Receptors in Human Immunodeficiency Virus Infection: Pathways to Protection or Doors to Disappointment?. Current HIV Research, 2009, 7, 487-496.	0.5	1